Immunex, Seattle, a small biotechnology company, stumbles into a hugely successful and ground-breaking product. More than $ 300 billion market in the United States – Enbrel, a tumor necrosis factor, is immediately recognized as the most effective treatment for rheumatoid arthritis. After nearly 20 years of unprofitability Enbrel is a lifesaver for Immunex. But it could also become the worst nightmare of the company. Immunex, starving after years of cash, it has not succeeded in the production skills to build t … Read more »

Immunex, Seattle, a small biotechnology company, stumbles into a hugely successful and ground-breaking product. More than $ 300 billion market in the United States – Enbrel, a tumor necrosis factor, is immediately recognized as the most effective treatment for rheumatoid arthritis. After nearly 20 years of unprofitability Enbrel is a lifesaver for Immunex. But it could also become the worst nightmare of the company. Immunex, starved of cash after years, it has been unable to build up the production capabilities to meet the sudden and massive demand for its drugs.
«Hide

from
Alicia Löffler,
S. Geetha Krishnan M.D.
Source: Kellogg School of Management
20 pages.
Release Date: 1 January 2004. Prod #: KEL069-PDF-ENG
Enbrel: The Sting of Success HBR case solution

[related_post themes="flat"]